How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis

0 SAR
Checkout

Overview

Discover how Ebglyss (Lebrikizumab) works as a targeted IL-13 inhibitor in the treatment of Atopic Dermatitis (AD). Learn more about Ebglyss unique mechanism of action, binding with high affinity to IL-13 and slow dissociation rate1-12.

This Class for

  • Physician
  • Resident / Fellow

What I will learn?

  • Enhance awareness and clinical understanding among targeted healthcare professionals regarding Atopic Dermatitis (AD) and the differentiated role of Ebglyss (lebrikizumab) in the management of moderate-to-severe AD.




    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
    24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
    For further information, please contact:
    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
    Please go to PDF Material for prescribing information

    PP-LK-SA-0032

Related Classes